Rinvoq ER 45 MG tablet UU 28S
Ended Awarded
- Contract number
- SPE2DB25FXA27
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,202
Award facts
- Contract value 100% obligated
- $14,202.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,202.34 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide.
RINVOQ ER (upadacitinib) is a Janus kinase (JAK) inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Health Agency's medical supply requirements for active-duty personnel, veterans, and military beneficiaries. AmerisourceBergen's extensive portfolio of federal pharmaceutical contracts demonstrates its critical role in the DLA Medical Supply Chain, with the company consistently delivering competitively awarded orders across multiple therapeutic domains. The DLA Troop Support is advancing its Pharmaceutical Prime Vendor Global Program Generation V strategy, which contemplates multiple regional awards to support comprehensive global military healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FXA27?
SPE2DB25FXA27 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FXA27 worth?
The government has obligated $14,202 on SPE2DB25FXA27.
Is contract SPE2DB25FXA27 an order under another contract?
Yes. SPE2DB25FXA27 is a delivery order under SPE2DB22D3501, an indefinite delivery contract.
Was contract SPE2DB25FXA27 competed?
The extent of competition for SPE2DB25FXA27 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award